FDA Fast-Tracks Review of 3 New Immunotherapy Options for Esophageal Cancer Patients
The U.S. Food & Drug Administration has granted Priority Review for the use of immunotherapies in three new designations for [...]
Hope is Important
These are challenging times. And we at ECAN are keeping our focus trained on the positive difference we can [...]
Immunotherapy Breakthroughs for Esophageal Cancer Patients
The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for [...]
Barrett’s Esophagus and Esophageal Adenocarcinoma can run in Families
The familial connection is one of the Strongest Indicators of Risk according to Experts. ECAN spoke with the Leading Researcher [...]
Don’t Be a Turkey!
Thanksgiving is during GERD Awareness Week! Show your gratitude by sharing a life-saving message with someone you are thankful for! [...]
ECAN Advocates Convince Congress to Include Esophageal Cancer in a Multi-Million Dollar Research Fund
For the second year in a row, thousands of ECAN advocates made their voices heard and convinced lawmakers in the [...]